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The authors aimed to compare renal function by estimated
glomerular filtration rate and albuminuria in 3 groups of
women: nulliparous women, women with a history of
normotensive pregnancies, and women with a history of at
least one hypertensive pregnancy. Women who participated
in the second Family Blood Pressure Program Study visit
(2000–2004) and had serum creatinine and urine albumin
measurements (n=3015) were categorized as having had no
pregnancy lasting >6 months (n=341), having had only
normotensive pregnancies (n=2199), or having had at least
1 pregnancy with hypertension (n=475) based on a stan-
dardized questionnaire. Women who reported having had at
least one pregnancy with hypertension were significantly
more likely to be hypertensive (75.6% vs 59.4%, P<.001),
diabetic (34.2% vs 27.3%, P .001), and have higher body
mass index (32.8 vs 30.5, P<.001) than those who reported
normotensive pregnancies. There was a significantly greater
risk of microalbuminuria (urine albumin-creatinine ratio
>25 mg/g) in those who reported at least one pregnancy
with hypertension (odds ratio, 1.37; confidence interval,
1.02–1.85; P=.04) than in those with normotensive pregnan-
cies, after adjusting for risk factors for chronic kidney and
cardiovascular disease. Hypertension in pregnancy is asso-
ciated with an increased risk of future microalbuminuria. J
Clin Hypertens (Greenwich). 2013;15:617–623. ª2013 Wiley
Periodicals, Inc.
Hypertensive pregnancy disorders affect 5% to 10% of
pregnancies and encompass a spectrum of disease
phenotypes, including preeclampsia, a form of hyper-
tension unique to pregnancy.1 Preeclampsia can occur
either de novo or superimposed on chronic hypertension
after 20 weeks of gestation, and is characterized by a
new-onset or worsening of preexisting proteinuria.2,3
Preeclampsia and its convulsive form eclampsia, remain
one of the major causes of maternal and fetal morbidity
and mortality. Chronic hypertension that persists during
pregnancy and gestational hypertension, defined as
hypertension occurring for the first time during the
second half of pregnancy in the absence of proteinuria,
usually have more benign courses. These disorders likely
reflect a spectrum of disease marked by endothelial
dysfunction initiated by both maternal and uteroplac-
ental factors.4,5
To date, case-control and registry-based cohort stud-
ies have suggested that women with histories of hyper-
tensive pregnancy disorders, and preeclampsia, in
particular, are at risk for future cardiovascular disease
(CVD).6,7 Recent data have also suggested that women
with preeclampsia may be at risk for chronic kidney
disease (CKD). Several cohort studies have demon-
strated that a history of preeclampsia is associated with
an increased risk of microalbuminuria,8,9 which is an
important risk factor for both cardiovascular mortal-
ity,10 and the initiation and progression of CKD.11,12 A
meta-analysis published in 2010 of the 7 largest cohort
studies of preeclamptic mothers found an increased
relative risk of increased albumin excretion in women
with a history of preeclampsia vs those with no history
of hypertension in pregnancy.13 The current available
studies are limited by small sample size, phenotypic
heterogeneity, and few adjust for the presence of major
risk factors for CKD, including diabetes mellitus or pre-
existing hypertension.
In this study, our goal was to assess evidence of CKD
among women in the large, multiracial cohort of the
Family Blood Pressure Program (FBPP) study based on
their reported history of hypertension in pregnancy. We
wanted to examine whether a history of hypertension in
pregnancy is an independent risk factor for kidney
dysfunction as evaluated by the estimated glomerular
filtration rate (eGFR) and spot urine albumin-creatinine
ratio (UACR), after controlling for traditional risk
factors for CKD and CVD.
METHODS
Participants
This study included 3015 patients from 1600 sibships
who participated in the FBPP study’s second examina-
tion conducted between 2000 and 2004. The FBPP
study was established in 1995 by the National Heart,
Lung, and Blood Institute (NHLBI) to identify genetic
factors that contribute to hypertension by recruiting
sibships of various ethnic backgrounds, including
Address for correspondence: Vesna D. Garovic, MD, Division of
Nephrology and Hypertension, Mayo Clinic, 200 First Street SW,
Rochester, MN 55905
E-mail: garovic.vesna@mayo.edu
Manuscript received: January 24, 2013; revised: March 20, 2013;
accepted: March 20, 2013
DOI: 10.1111/jch.12116
Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension Vol 15 | No 9 | September 2013 617
ORIGINAL PAPER
non-Hispanic whites, African Americans, Mexican
Americans, and Asian Americans of both Japanese and
Chinese descent. It comprises 4 separate networks:
GenNet, Genetic Epidemiology Network of Atheroscle-
rosis (GENOA), Hypertension Genetic Epidemiology
Network (HyperGen), and Stanford Asian Pacific
Program in Hypertension and Insulin Resistance (SAP-
PHIRe). There were 13 field centers throughout the
United States. The recruitment strategies and character-
istics of each cohort have been described previously.14
This study included patients from GENOA, HyperGen,
and SAPPHIRe for whom urinary albumin and creati-
nine (Cr) measurements were available. Briefly,
GENOA recruited sibships with at least two individuals
with hypertension diagnosed before age 60 and included
3 field centers: Jackson, MI; Starr County, TX; and
Rochester, MN, which recruited African Americans,
Mexican Americans, and non-Hispanic whites, respec-
tively. HyperGen recruited hypertensive sibships and, if
available, their parents and  1 untreated adult off-
spring from 5 field centers: Birmingham, AL; Forsyth
County, NC; Framingham, MA; Minneapolis, MN; and
Salt Lake City, UT. Lastly, SAPPHIRe recruited sibships
from Asian Pacific populations and included two types
of sibship pairs: concordant (both siblings with hyper-
tension) and discordant (one sibling with and one
without hypertension).
The phase II study examination included a question-
naire regarding participants’ personal and family med-
ical histories, medication history, and history of
menopause and hormone replacement therapy from
female participants. The study visit occurred any time
between December 2000 and November 2004 for the
patients in this study. In addition, the questionnaire
included questions regarding pregnancy and hyperten-
sion (described below).
Study Visits
All participants gave informed consent and the institu-
tional review board at each clinic site approved all
protocols. The questionnaires were administered via
personal interviews with trained examiners. They
underwent a standard physical examination and blood
and urine tests. The height was measured while the
patient was standing against a vertically mounted ruler
without shoes on, and weight was measured on a
balance scale. Body mass index (BMI) was calculated as
weight (kg)/height (m).2 All patients had their systolic
and diastolic blood pressures (BPs) measured using an
automatic oscillometric BP measurement device. Three
measurements of BP and heart rate were made for each
patient.
At the phase II examination visit, the diagnosis of
hypertension was confirmed if the average systolic BP or
diastolic BP was >140 mm Hg or 90 mm Hg, respec-
tively, or if there was a prior diagnosis of hypertension
and use of prescription antihypertensive medication was
reported. The diagnosis of diabetes was determined by
self-report and an “ever smoked” status was defined as
having smoked >100 cigarettes at any point in the
patient’s lifetime. The diagnosis of CVD was established
by self-report of myocardial infarction, coronary bypass
surgery, coronary angioplasty, balloon dilatation, or
stent placement. The highest grade of completed
education was assessed, as was the use of prescription
medications in the last month.
The eGFR was calculated using the CKD Epidemiol-
ogy Collaboration (CKD-EPI) equation, and a decreased
GFR was defined by an eGFR <60 mL/min/1.73 m2.15
Microalbuminuria was defined as a UACR  25 mg/g
creatinine (Cr) on a spot urine sample, which represents
the 95th percentile for women, and corresponds to an
albumin excretion rate of >30 lg/min.16 Proteinuria
was defined as UACR  300 mg/g Cr on a spot urine
sample. Elevated C-reactive protein (CRP) levels were
defined as >0.3 mg/dL17 and were only available for
GENOA patients.
Pregnancy Questionnaire
A questionnaire regarding hypertension and pregnancy
that has been previously validated18 was administered
to all networks. In brief, female patients were queried as
to whether they had a pregnancy lasting >6 months and
whether they had developed hypertension during any of
their pregnancies. The participants were asked whether
they had a history of preeclampsia or protein in the
urine during any hypertensive pregnancy.
Laboratory Methods
Blood was drawn by venipuncture and urine was
collected after an overnight fast of at least 8 hours.
Serum and urine Cr were measured using the Jaffe assay,
and urine albumin was determined using an immuno-
turbidity method implemented on an automated chem-
istry analyzer (Hitachi 911; Roche Diagnostics,
Indianapolis, IN). Serum total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride concen-
trations were all measured by standard methodology,
also using the Hitachi 911 Chemistry Analyzer. Low-
density lipoprotein (LDL) was calculated using the
Friedewald equation when the triglyceride concentra-
tion was >400 mg/dL. CRP was measured by a highly
sensitive latex particle-enhanced immunoturbidimetric
assay.19
Statistical Analysis
We used Wilcoxon-rank sum tests to assess pairwise
differences in age between the pregnancy groups and
chi-square tests for network, race, and education
variables. Because of differing recruitment strategies
among the networks, all analyses were adjusted for age,
race, and network before assessing differences in other
measures between pregnancy groups. We used linear
regression models for continuous measures and logistic
regression models for categorical measures, to adjust
for age, race, and network, and reported adjusted
meanstandard deviation or adjusted percentages
within each pregnancy group. These models were fit
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with generalized estimating equations to account for
sibling relationships. Quantitative variables with
skewed distributions were log-transformed for the
models. We also fit additional models for the quantita-
tive and categorical measures of CKD that were
adjusted for education, smoking, hypertension, use of
hormone replacement therapy, diabetes, BMI, family
history of hypertension or CVD, use of antihypertensive
medications, and use of angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor blockers
(ARBs), in addition to age, race, and network. The use
of antihypertensive medications, ACE inhibitors, and
ARBs, were only available in the GENOA network and
were coded as 0 for patients in other networks.
RESULTS
A total of 3015 women from 3 of the 4 networks
(GENOA, HyperGen, and SAPPHIRe) participated in
the second study visit and had UACR and Cr values
measured. Of the available patients, 2674 (89%)
women reported having at least one pregnancy lasting
>6 months and 475 (16%) women reported having
hypertension in at least 1 pregnancy. In women with a
history of hypertensive pregnancy, the median (inter-
quartile range) time from the first pregnancy with
hypertension until the visit when UACR was measured
was 27 (19–37) years. In those who reported having
hypertension in pregnancy, 144 (31%) reported pre-
eclampsia. Nulliparous women were more likely to have
completed higher levels of education than women with
at least one pregnancy (P<.001). Non-Hispanic whites
made up a larger proportion of those who were
nulliparous (42%) compared with both the normoten-
sive and hypertensive pregnancy groups (30% for both,
P<.001). Alhough there were only 146 Japanese patients
total, the proportion of Japanese patients in the nullip-
arous group was significantly higher (8%) than in
the normotensive (5%, P=.01) and hypertensive (3%,
P=.002) pregnancy groups. The other demographic
characteristics of the patients divided by hypertension-
in-pregnancy status are shown in Table I.
After adjusting for age, race, and network, compared
with women with a history of normotensive pregnancy,
those with hypertensive pregnancies had a significantly
higher prevalence of hypertension (75.6% vs 59.4%,
P<.001), use of antihypertensive medications (80.8% vs
61.3%, P<.001), use of ACE inhibitors/ARBs (49.9% vs
33.0%, P<.001), diabetes (34.2% vs 27.3%, P<.001),
and had a higher BMI (32.8 vs 30.5, P<.001) (Table II).
Compared with women with a history of normotensive
pregnancy, nulliparous women had a higher prevalence
of hypertension (67.4% vs 59.4%, P=.001) and use of
antihypertensive medications (68.5% vs 61.3%,
P=.037). Estimated GFR was lower in nulliparous
women compared with those with normotensive preg-
nancies (88.4 vs 90.7 mL/min/1.73 m2, P=.01), but not
significantly different in normotensive pregnancies com-
pared with those with hypertensive pregnancies. The
mean eGFR was >60 mL/min/1.73 m2 in all 3 groups of
women. UACR was significantly higher in women with
a hypertensive pregnancy compared with both normo-
tensive and nulliparous women (7.1 vs 5.4 mg/g Cr for
normotensive and nulliparous women, P=.003 and
P=.029, respectively). There was also a significant
increase in the prevalence of microalbuminuria (19%
vs 12.8%, P<.001) and proteinuria (5.4% vs 2.9%,
P=.008) in patients with hypertensive vs normotensive
pregnancies.
Renal Outcomes
We performed linear regression models on the following
continuous measures of CKD—log(UACR), log(Cr),
TABLE I. Age, Race, Network, and Education Differences by Pregnancy Status
Variable No.
Nulliparous
(n=341)
Normotensive
Pregnancy
(n=2199)
Hypertensive
Pregnancy
(n=475)
Normotensive
vs Nulliparous
P Value
Hypertensive
vs Nulliparous
P Value
Hypertensive vs
Normotensive
P Value
Age 3015 51 (40–63) 59 (50–66) 56 (46–64) <.001 <.001 <.001
Race
Non-Hispanic white 3015 144 (42) 664 (30) 142 (30) <.001 <.001 .46
Hispanic 68 (20) 531 (24) 114 (24)
Non-Hispanic black 102 (30) 900 (41) 204 (43)
Japanese 27 (8) 104 (5) 15 (3)
Network
GENOA 3015 216 (63) 1806 (82) 400 (84) <.001 <.001 .29
HyperGEN 98 (29) 289 (13) 60 (13)
SAPPHIRe 27 (8) 104 (5) 15 (3)
Education
Less than high school education (8 y) 3015 40 (12) 454 (21) 87 (18) <.001 <.001 .27
Partial high school education (9–11 y) 15 (4) 227 (10) 62 (13)
High school graduate or GED (12 y) 82 (24) 617 (28) 129 (27)
Post–high school education (>12 y) 204 (60) 901 (41) 197 (41)
Abbreviations: GENOA, Genetic Epidemiology Network of Atherosclerosis; HyperGen, Hypertension Genetic Epidemiology Network; SAPPHIRe,
Stanford Asian Pacific Program in Hypertension and Insulin Resistance.
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and eGFR—adjusted for education status, smoking
status, current hypertension, use of antihypertensives
and ACE inhibitors/ARBs (GENOA patients only), use
of hormone replacement therapy, diabetes mellitus, log
(BMI), and family history of hypertension and CVD
(Table III), in addition to age, race, and network. Those
with a normotensive pregnancy had a significantly lower
predicted serum Cr (P=.01) and higher predicted eGFR
(P=.02) than the nulliparous patients. There was no
significant difference in predicted UACR between the
normotensive and nulliparous groups. There was no
significant difference in predicted log(UACR), log(Cr),
or eGFR between those with hypertensive pregnancies,
as compared with normotensive or nulliparous patients.
In the logistic regression model (Table IV), we
assessed the effect of a history of hypertensive preg-
nancy vs normotensive pregnancy and history of
normotensive pregnancy vs nulliparous state on the risk
of microalbuminuria (UACR >25 mg/g Cr) as a cate-
gorical variable. The logistic regression models were
TABLE II. Age, Race, and Network-Adjusted MeanStandard Deviations or Percentages by Pregnancy Status
Variable No.
Nulliparous
(n=341)
Normotensive
Pregnancy
(n=2199)
Hypertensive
Pregnancy
(n=475)
Normotensive
vs Nulliparous
P Value
Hypertensive
vs Nulliparous
P Value
Hypertensive vs
Normotensive
P Value
Ever smoked 3015 30.1 31.1 27.4 .73 .40 .11
Current hypertension 3011 67.4 59.4 75.6 .001 <.001 <.001
Antihypertensive medications 2422 68.5 61.3 80.8 .037 <.001 <.001
ACE inhibitors/ARBs 2422 36.9 33.0 49.9 .28 .002 <.001
Diabetes 3014 26.7 27.3 34.2 .84 .027 <.001
Log(BMI) 3009 3.440.24 3.420.20 3.490.21 .10 <.001 <.001
BMIa 31.1 30.5 32.8
Hormone replacement therapy 3010 23.0 23.4 21.9 .87 .70 .47
Birth control 2995 3.3 3.1 2.8 .79 .62 .73
Log(total cholesterol) 3015 5.290.21 5.280.19 5.260.21 .43 .09 .14
Total cholesterol, mg/dLa 198.0 196.0 193.0
Log(triglycerides) 3015 4.840.51 4.820.51 4.850.49 .47 .68 .13
Triglycerides, mg/dLa 125.2 122.5 127.1
Log(LDL cholesterol) 2947 4.740.34 4.740.31 4.710.35 .75 .14 .09
LDL cholesterol, mg/dLa 114.6 113.9 110.6
HDL cholesterol, mg/dL 3015 56.216.0 55.515.4 54.615.9 .40 .14 .28
Log(Cr) 3015 0.580.13 0.560.13 0.570.17 .005 .50 .07
Creatinine, mg/dLa 0.79 0.75 0.77
Estimated GFR (CKD-EPI), mL/min/1.73 m2 3015 88.416.4 90.716.4 89.719.3 .014 .32 .24
Log(UACR) 3015 1.851.38 1.851.43 2.091.61 .96 .029 .003
UACR, mg/g Cra 5.4 5.4 7.1
Elevated UACR ( 25) 3015 14.3 12.8 19.0 .48 .10 <.001
Elevated UACR (>300) 3015 3.8 2.9 5.4 .50 .38 .008
Family history of hypertension 3015 77.6 74.8 80.9 .28 .22 .001
Family history of CVD 3015 40.1 41.3 44.7 .60 .10 .07
Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; BMI, body mass index; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration; Cr, creatinine; CVD, cardiovascular disease; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; LDL,
low-density lipoprotein; UACR, spot urine albumin-creatinine ratio.
aVariables were log-transformed for the linear models used to estimate the adjusted means in each pregnancy group. Adjusted meanstandard
deviations are shown on the log-scale, but for ease of interpretation, the adjusted means are also shown after being un-transformed.
TABLE III. Estimated Mean Difference in Renal Outcomes for Pregnancy Groups
Renal Parameter
Normotensive vs Nulliparous Hypertensive vs Nulliparous Hypertensive vs Normotensive
Difference P Value Difference P Value Difference P Value
Log(UACR) 0.0229 .78 0.1402 .18 0.1173 .13
Log(Cr) 0.0194 .011 0.0134 .20 0.0060 .46
eGFR (CKD-EPI) 2.133 .022 1.900 .13 0.2337 .81
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; eGFR, estimated glomerular filtration rate; UACR, spot
urine albumin-creatinine ratio.
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adjusted for the same potential confounders as the linear
regression models. There was a significant increase in
the risk of microalbuminuria in those with a history of
hypertensive pregnancy (odds ratio [OR], 1.37; 95%
confidence interval [CI], 1.02–1.85; P=.04) vs those
with a normotensive pregnancy. There was no signifi-
cant difference in the predicted risk of microalbumin-
uria in those with normotensive pregnancies vs
nulliparous patients (OR, 0.85; CI, 0.58–1.25; P=.41)
or those with hypertensive pregnancies vs nulliparous
patients (OR, 1.17; CI 0.74–1.84; P=.50). We evaluated
our models to see if there was any difference in the
above outcomes—log(UACR), log(Cr), eGFR, and
UACR >25 mg/g Cr—between those with a reported
history of preeclampsia vs those with a history of
hypertensive pregnancy alone and there were no signif-
icant differences.
We have previously reported elevated CRP levels in
patients with hypertensive pregnancies vs those with
normotensive pregnancies in GENOA patients6 (pre-
sented as abstract, article in press). CRP was only
available in the GENOA patients in this study but in
subset analyses among the GENOA patients, we found
no significant interaction between hypertensive preg-
nancy and the presence of elevated CRP levels on the
development of microalbuminuria (P=.16 for log
(UACR) as the outcome and P=.12 for UACR
>25 mg/g Cr as the outcome). In addition, adjusting
for elevated CRP only minimally changed the estimated
differences in microalbuminuria among the pregnancy
groups.
DISCUSSION
In this study, we present evidence that women with a
history of hypertension in pregnancy are at significantly
increased risk for microalbuminuria later in life com-
pared with women with normotensive pregnancies. This
relationship remained significant after adjustment for
significant risk factors for both CKD and CVD.
Studies on the long-term effects of hypertensive
pregnancy on the kidney have shown differing results.
Several previous cohort and case-control studies have
suggested that there is an increased risk for microalbu-
minuria after hypertensive pregnancy8,9,20 and this has
been confirmed in a recent meta-analysis.13 At least two
other studies have suggested no increased risk for
microalbuminuria.21,22 One small study of 10 women
with HELLP syndrome (a particularly severe form of
preeclampsia, characterized by hemolysis, elevated liver
enzymes, and low platelet count) showed no difference
in UACR at 5 years of follow-up between cases and
controls;21 however, this was a small study and HELLP
syndrome is not typically characterized by significant
albuminuria. Another study by Lampinen and col-
leagues22 assessed the 5-year outcomes after index
pregnancy in 30 cases and 21 controls, and excluded
patients with chronic hypertension, renal disease, dia-
betes, or gestational diabetes. They did not find an
increased incidence of microalbuminuria, but their
inclusion criteria may have been too strict. The strength
of our study is that this cohort has well-characterized
data on comorbidities with known associations to
microalbuminuria. This population included approxi-
mately 3000 patients, giving it sufficient power to detect
the expected association between microalbuminuria and
the relevant comorbidities, such as diabetes and hyper-
tension, as is seen in the logistic regression model shown
in Table IV.
Epidemiologic studies have shown that microalbu-
minuria is an important risk factor for CKD and CVD.
Several studies have shown that patients with microal-
buminuria, both in diabetics and the general population,
are at an increased risk for progression of CKD.11,23–25
In addition, it has long been considered a marker of
general endothelial dysfunction, as first described in
type 1 diabetic patients and referred to as the Steno
TABLE IV. Logistic Regression Model Predicting
UACR >25 mg/g Cr by Pregnancy Groups
Parameter OR (95% CI) P Value
Hypertensive pregnancy
(vs normotensive)
1.37 (1.02–1.85) .038
Normotensive pregnancy
(vs nulliparous)
0.85 (0.58–1.25) .413
Network .001
HyperGen reference
GENOA 0.95 (0.51, 1.78) .875
SAPPHIRe 4.88 (2.06, 11.53) <.001
Race <.001
Non-Hispanic white reference
Hispanic 2.37 (1.44–3.89) <.001
Non-Hispanic black 3.36 (2.25–5.00) <.001
Age, per 10 y 1.06 (0.92–1.21) .434
Education level .032
High school graduate or GED (12 y) reference
Less than high school education
( 8 y)
0.99 (0.68, 1.46) .977
Partial high school education (9–11 y) 1.17 (0.80–1.70) .426
Post–high school education (>12 y) 0.69 (0.51–0.94) .018
Ever smoked 0.93 (0.72–1.19) .555
Current hypertension 2.29 (1.53–3.43) <.001
Hormone replacement therapy 0.68 (0.50–0.92) .013
Antihypertensive medications
(GENOA only)
1.30 (0.86–1.96) .220
ACE inhibitors/ARBs (GENOA only) 0.74 (0.55–0.98) .036
Diabetes 4.19 (3.19–5.52) <.001
Log(BMI) 0.86 (0.49–1.54) .620
Family history of hypertension 1.07 (0.81–1.42) .641
Family history of CVD 0.97 (0.75–1.24) .800
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angioten-
sin receptor blocker; BMI, body mass index; CI, confidence interval;
CVD, cardiovascular disease; GENOA, Genetic Epidemiology Net-
work of Atherosclerosis; HyperGen, Hypertension Genetic
Epidemiology Network; OR, odds ratio; SAPPHIRe, Stanford Asian
Pacific Program in Hypertension and Insulin Resistance; UACR, spot
urine albumin-creatinine ratio.
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hypothesis.26 This has been validated more recently in
physiologic studies showing impaired endothelium-
dependent, endothelium-independent, and flow-mediated
vasodilation of the brachial artery in diabetic patients
with microalbuminuria.27,28 Microalbuminuria is a
significant independent risk factor for CVD in both
diabetics and nondiabetics.29,30 Taken together with our
other studies from this same cohort of patients showing
increased risk for CVD and elevated C-reactive pro-
tein6,7 in patients with a history of hypertensive preg-
nancy, this study lends further evidence to the
hypothesis that a hypertensive pregnancy may inflict
long-term, clinically significant vascular changes in the
kidney that manifests as microalbuminuria up to 3
decades later.1 This may in part be due to systemic
inflammatory mediators, but in our subset analysis of
GENOA patients alone, there was no significant inter-
action between hypertensive pregnancy and elevated
CRP levels on the development of microalbuminuria,
and the ORs for those with hypertensive vs normoten-
sive pregnancies were only minimally changed when
adjusting for elevated CRP. This suggests that inflam-
mation alone cannot account for the relationship
between hypertension in pregnancy and microalbumin-
uria. Further study into other inflammatory markers,
such as lipoprotein(a) and homocysteine, followed
prospectively after a hypertensive pregnancy as
compared with a normotensive pregnancy, may help
elucidate this relationship.
We did not find a statistically significant difference in
serum Cr or eGFR in patients with a hypertensive
pregnancy vs those with a normotensive pregnancy.
This may in part be due to the fact that serum Cr is an
indicator of impaired renal function, whereas microal-
buminuria may be a marker of renal damage that can be
present prior to the decline in function. We also did not
detect a difference in log(UACR) between hypertensive
and normotensive or nulliparous patients when viewed
as a continuous variable, but did see a difference when
microalbuminuria was dichotomized as greater than or
less than 25 mg/g Cr. This may be due to the fact that
the majority of women in all groups had values within
the normal range of UACR and thus the relationship
with hypertensive pregnancy was masked.
We did observe a slightly decreased serum Cr and
higher eGFR in those with normotensive pregnancies vs
nulliparous women. While it is a well-established
phenomenon that GFR increases and serum Cr
decreases during normal pregnancy,31 there are few
data on the long-term renal function after normal
pregnancy. Our data would either suggest that this
hyperfiltration persists post-delivery or that normoten-
sive pregnancy is in some way protective against a
decline in GFR. We do not have information on the
reasons that a woman may have remained nulliparous,
although these reasons may contain potential confound-
ers unaccounted for in our models. It has been shown
that hyperfiltration, even in the early stages of hyper-
tension, is associated with the development of microal-
buminuria. In the Hypertension and Ambulatory
Recording Venetia Study (HARVEST), 502 never-
treated patients with stage I hypertension (systolic BP
140–159 mm Hg, diastolic BP 90–99 mm Hg) were
followed prospectively for approximately 8 years. It
was shown that patients with hyperfiltration, defined as
a Cr clearance >150 mL/min/1.73 m2, had an increased
risk for the development of microalbuminuria (adjusted
hazard ratio, 4.0; 95% CI, 2.1–9.2; P<.001) vs patients
with normal filtration.32 To analyze whether hyperfil-
tration was in part responsible for the risk of microal-
buminuria observed in our study, we fit the log(Cr) and
eGFR regression models with an additional adjustment
for log(UACR), and the log(UACR) and UACR >25 mg/
g Cr regression models with and additional adjustment
for log(Cr). Even after the additional adjustment, the
relationships between hypertensive pregnancy and the
renal outcomes remained similar.
STUDY LIMITATIONS
Our study has several limitations. The majority of this
cohort was recruited on the basis of a diagnosis of
hypertension and therefore has a higher incidence of
hypertension than the general population. The medical
history and exposure status were ascertained via survey,
which introduces the potential for recall bias. In order
to minimize the influence of recall bias, standardized
protocols and questionnaires were used. Women have
been shown to have reasonable recall of pregnancy-
related complications.33 The survey regarding hyper-
tension in pregnancy used in this particular study has
been validated previously in patients with a history of
preeclampsia >20 years in the past and was found to
have 80% sensitivity and 96% specificity.18 This
indicates that patients would be more likely to under-
report rather than over-report their exposure, which
would result in an underestimation of the true risk of
microalbuminuria.
Despite these limitations, our study shows that
hypertensive pregnancy is an independent risk factor
for microalbuminuria after controlling for known risk
factors for CKD and CVD. In the most recent
guidelines from the American Heart Association in
2011, preeclampsia was formally identified as a major
risk factor for CVD in women.34 The question
remains, what tools should we use to identify women
at the highest risk for CVD? Testing for microalbu-
minuria is simple, inexpensive, and noninvasive and
has been shown to be cost-effective when used to
prevent renal and cardiovascular outcomes.35,36
Women with a hypertensive pregnancy have been
shown to be at an increased risk for renal and CVD,
and therefore routine screening for microalbuminuria
may be a way to monitor and intervene early in this
population. Another unanswered question is whether
intervention with medications, such as ACE inhibitors,
in the postpartum period after a mother has finished
breastfeeding, can prevent the development of micro-
albuminuria and lower subsequent CVD risk.
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CONCLUSIONS
Hypertension in pregnancy is associated with an
increased risk of microalbuminuria independent of
traditional risk factors for CKD and CVD. The body
of evidence that this is a population at risk for
significant cardiovascular and renal disease continues
to grow and may eventually lead to standardized
guidelines for the long-term follow-up of women with
a hypertensive pregnancy.
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